Spero Therapeutics, Inc.
SPRO
$0.71
-$0.0152-2.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -79.54% | -47.12% | 275.44% | 347.90% | 54.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.54% | -47.12% | 275.44% | 347.90% | 54.98% |
| Cost of Revenue | 87.14% | 13.57% | 149.47% | 93.03% | 227.62% |
| Gross Profit | -359.15% | -48.64% | -99.12% | -16.71% | -25.54% |
| SG&A Expenses | 9.68% | -8.93% | -9.24% | -19.13% | -0.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.12% | 45.07% | 87.48% | 42.67% | 6.51% |
| Operating Income | -141.26% | -651.39% | -47.87% | 1.72% | 95.43% |
| Income Before Tax | -139.94% | -1,654.23% | -49.92% | 4.50% | 92.66% |
| Income Tax Expenses | -25.06% | -113.12% | -- | -- | -- |
| Earnings from Continuing Operations | -140.80% | -435.01% | -49.92% | 4.50% | 91.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.80% | -435.01% | -49.92% | 4.50% | 91.22% |
| EBIT | -141.26% | -651.39% | -47.87% | 1.72% | 95.43% |
| EBITDA | -141.23% | -634.28% | -49.12% | 1.58% | 94.60% |
| EPS Basic | -139.65% | -421.05% | -46.07% | 6.29% | 75.78% |
| Normalized Basic EPS | -137.16% | -494.13% | -46.12% | 6.27% | 77.52% |
| EPS Diluted | -139.87% | -421.05% | -46.07% | 4.99% | 75.34% |
| Normalized Diluted EPS | -137.23% | -494.13% | -46.12% | 6.27% | 77.17% |
| Average Basic Shares Outstanding | 2.90% | 2.68% | 2.64% | 1.90% | 8.79% |
| Average Diluted Shares Outstanding | 2.69% | 2.68% | 2.64% | 1.90% | 9.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |